Study details
Enrolling now
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
Cerus Corporation
NCT IDNCT07015437ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
70
Study length
about 1.1 years
Ages
18+
Locations
2 sites in OH, VA
What this study is about
Researchers are testing a new blood product called INTERCEPT. It involves infusing healthy volunteers with INTERCEPT red blood cells, which are prepared using the INTERCEPT Blood System. The trial will last 391 days and measure how well these new red blood cells work after being stored for 35 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Infusion of autologous radiolabeled RBCs
- 2.Use INTERCEPT Blood System for RBCs
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
intravenous